Obesity and diabetes: the final frontier - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36710450/
Although bariatric surgery has been the primary approach to treating obese individuals, the emergence of agents impacting the brain satiety centers now promises effective, non-invasive treatment of obesity for individuals...
Expert opinion: Although bariatric surgery has been the primary approach to treating obese individuals, the emergence of agents impacting the brain satiety centers now promises effective, non-invasive treatment of obesity for individuals with and without diabetes. The GLP-1 receptor agonists have assumed the primary role in treating obesity...
Share
The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36721366/
Weight-lowering pharmacotherapies provide an option for weight management; however, their effects on physical activity, function, and cardiorespiratory fitness are not fully understood. We conducted a systematic review and meta-analysis of...
Conclusions/Relevance: None of the studies reported a physical activity outcome, and only one study reported objectively measured cardiorespiratory fitness. Improvements in self-reported physical function were observed with weight loss therapy, but the effect on physical activity or objectively measured physical function and fitness could not...
Share
Efficacy and safety of semaglutide for weight management: evidence from the STEP program
Source : https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2147326
ABSTRACT ABSTRACT Obesity is a global health challenge. It is a multifactorial, complex, and progressive disease associated with various health complications and increased mortality. Lifestyle modifications are central to weight...
Relevance: Semaglutide 2.4 mg once weekly was generally well tolerated in adults with obesity, or overweight with comorbidities, without T2D (STEP 1, 3, 4, and 5), and in adults with T2D and overweight or obesity (STEP 2).
Share
-
Dr Hamid3yrObesity is a global health challenge. It is a multifactorial, complex, and progressive disease associated with various health complications and increased mortality
Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg
Source : https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2149005
Pharmacotherapy is typically recommended as an adjunct to lifestyle intervention to help achieve and maintain weight loss for those with obesity (body mass index [BMI] of ≥30 kg/m 2) or...
Conclusions/Relevance: The availability of once-weekly semaglutide 2.4 mg for weight management, as an adjunct to increased physical activity and a reduced-calorie diet that is individualized, scientifically supported, and relevant to the patient, represents an important advance in therapeutic options for patients with overweight or obesity.
Share
-
Dr Hamid3yrObesity is a complex, chronic disease that represents a global public health challenge
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program
Source : https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2150006
ABSTRACT ABSTRACT Obesity negatively impacts patients' health-related quality of life (QOL) and is associated with a range of complications such as type 2 diabetes (T2D), cardiovascular disease, and sleep apnea,...
Conclusions/Relevance: Taken together, these are important considerations for primary care when incorporating pharmacotherapy for weight management.
Share